BIOCRYST PHARMACEUTICALS INC (BCRX) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-06

Key Insights

BioCryst announced Q1 2026 financial results and corporate developments on May 6, 2026, indicating the company is actively managing operations and maintaining investor communication through earnings releases.
The filing indicates a conference call and webcast were scheduled to discuss financial results and corporate developments, suggesting management engagement with investors regarding business performance and strategy.
The press release was furnished under Regulation FD Disclosure, meaning the information is being simultaneously disclosed to all investors to ensure fair and equal access to material information.

Want the newest filings?

This analysis covers the filing from 2026-05-06. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-02-26

BioCryst Pharmaceuticals reported its full year 2025 financial results, which appear to show continued growth and development of the company's pipeline.
The company highlighted recent corporate developments, which may indicate progress on key initiatives or products.
Investors will likely be interested in the details provided on the conference call and webcast, which could provide more insights into the company's performance and outlook.

Filed: 2026-01-23

BioCryst Pharmaceuticals has secured a $400 million term loan facility from Blackstone to finance the merger and provide working capital.
The term loan has a 5-year maturity with quarterly interest-only payments, and BioCryst has the option to capitalize a portion of the interest during the first 2 years.
The loan agreement includes customary covenants and events of default, which could restrict BioCryst's financial and operational flexibility if not met.

Filed: 2026-01-12

BioCryst Pharmaceuticals reported strong preliminary Q4 2025 and full year 2025 ORLADEYO net revenue, beating prior guidance and showing significant year-over-year growth.
The company provided guidance for full year 2026 ORLADEYO net revenue, total revenue, and operating expenses, giving investors visibility into the company's future performance.
BioCryst has a substantial cash position of $338 million as of December 31, 2025, providing ample resources to fund its operations and growth initiatives.

Filed: 2026-01-09

BioCryst Pharmaceuticals is increasing the wholesale acquisition cost (WAC) for its drug ORLADEYO by 9% from $44,484.33 to $48,487.92 per 28-day pack.
The price increase may positively impact the company's revenue and profitability, but could also affect patient access and affordability of the drug.
Investors should closely monitor the market reaction and potential impact on ORLADEYO sales volume and the company's overall financial performance.

Other reports for BIOCRYST PHARMACEUTICALS INC

Quarterly Report Insider Trading Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.